Grass Pollen Allergy Clinical Trial
Official title:
Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy
The study will evaluate the efficacy and safety of BM32 in grass pollen allergic subjects. It will test the hypothesis that either of two doses of BM32 will lead to a sustained relief off allergy symptoms over a two year study period.
The present study is designed to evaluate the efficacy and safety of a treatment with the recombinant vaccine BM32 during two consecutive grass pollen seasons. Efficacy evaluation will be performed on the basis of allergy symptoms and use of relief medication as well as based on immunological parameters. After patient assessment during a screening season, patients will be randomized to one of two doses of BM32 or placebo. Patients will receive three injections of BM32 pre-season and one post-season boost injection to maintain optimal allergen specific IgG responses. Outcome will be measured after both seasons individually. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05560698 -
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
|
N/A | |
| Completed |
NCT01445002 -
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
|
Phase 2 | |
| Completed |
NCT01830673 -
Regulatory T-cells After Subcutaneous Immunotherapy
|
N/A | |
| Active, not recruiting |
NCT04502966 -
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
|
Phase 2 | |
| Completed |
NCT00263601 -
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
| Completed |
NCT00264459 -
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
|
Phase 3 | |
| Completed |
NCT01308021 -
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
|
Phase 2 | |
| Completed |
NCT00773240 -
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
|
Phase 3 |